



COMPANY OVERVIEW

Titan Pharmaceuticals, Inc. was incorporated as a Delaware corporation in 1992. Titan previously focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura®, for the treatment of select chronic diseases for which steady state delivery of a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate ("EVA") and a drug substance. The resulting product is a solid matrix that is designed to be administered sub-dermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period.

Titan's first product based on the ProNeura technology was Probuphine® (buprenorphine implant), which is approved in the United States, Canada and the European Union ("EU") for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. While Probuphine continues to be commercialized in the EU (as Sixmo™) by another company that had acquired the rights from Titan, Titan discontinued commercialization of the product in the United States during the fourth quarter of 2020 and subsequently sold the product in September 2023.

In December 2021, Titan announced its intention to work with a financial advisor to explore strategic alternatives to enhance stockholder value, potentially including an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other transaction.

RECENT NEWS

Titan Pharmaceuticals Announces \$600,000 Private Placement of Convertible Preferred Stock

Jun 27 2025, 4:05 PM EDT

Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

Jun 3 2025, 8:45 AM EDT

STOCK OVERVIEW

Symbol	TTNP
Exchange	Nasdaq
Market Cap	4.43m
Last Price	\$4.85
52-Week Range	\$3.03 - \$14.80

08/14/2025 07:11 PM EDT

INVESTOR RELATIONS

Kate Beebe DeVarney, PhD
T: 650-989-2258

MANAGEMENT TEAM

Coming Soon

TITAN PHARMACEUTICALS, INC.

10 East 53rd St.
Suite 3001
New York, NY 10022
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and

uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.